Mirum Pharmaceuticals Inc (MIRM) Quote

Approbation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFIC

La Commission européenne accorde une autorisation de mise sur le marché au LIVMARLI pour le traitement de la PFIC chez les patients âgés de trois mois et plus. L’approbation fait suite à l’avis...

LIVMARLI von Mirum Pharmaceuticals wird in der Europäischen Union für Patienten mit PFIC zugelassen

Die Europäische Kommission erteilt LIVMARLI die Marktzulassung für die Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten. Die Zulassung erfolgt im Anschluss an ein positives...

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive opinion from CHMP concluding LIVMARLI’s clinical...

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only therapy indicated for CTX in the US Mirum...

Form 8-K - Current report

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus - VISTAS PSC interim analysis exceeds...

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on June 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

Form 4 - Statement of changes in beneficial ownership of securities

Les données à long terme des études LIVMARLI de Mirum sur l’ALGS et la PFIC présentées au congrès de l’EASL

- Les données montrent un bénéfice clinique soutenu après sept ans de traitement par LIVMARLI chez les patients atteints du syndrome d’Alagille - Les données d’extension à long terme des études...

Form 8-K - Current report

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension data from LIVMARLI PFIC studies highlight...